Med. praxi. 2011;8(7):321-324

Nonalcoholic steatohepatitis, possibilities of diagnosis and treatment of keratin fragments

prof.MUDr.Jan Lata, CSc.1, MUDr.Veronika Příbramská2
1 Interní klinika Lékařské fakulty Ostravské Univerzity Ostrava a FN Ostrava
2 Interní hepatogastroenterologická klinika FN Brno

Fatty liver disease that develops in the absence of alcohol abuse is increasingly recognised as a major health burden. Non-alcoholic steatohepatitis

is disease that histologically mimics alcoholic hepatitis. The diagnostic criteria continue to evolve and rely on the histologic

findings of steatosis, hepatocellular injury including lobular inflammation and the pattern of fibrosis in patients with minimal intake of

ethanol (< 20 g ethanol/day). Recently has been studied extensively as it is relatively frequent, and might lead to the development of liver

cirrhosis and hepatocellular carcinoma. The pathophysiologic basis is thought to be insulin resistance and this disease is considered to

be the hepatic manifestation of the metabolic syndrome. Exact non-invasive diagnosis is difficult and studies with keratin fragments

seems to be promising. Weight loss is up to now the only effective treatment.

Keywords: nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, keratin fragments, insulin-resistance, metabolic syndrome

Published: August 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lata J, Příbramská V. Nonalcoholic steatohepatitis, possibilities of diagnosis and treatment of keratin fragments. Med. praxi. 2011;8(7):321-324.
Download citation

References

  1. Ludwig TR, Viggiano DB, McGill, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hithrerto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
  2. Brent A. Neuschwander T, Stephen H, et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Konference. Hepatology 2003; 37(5): 1202-1219. Go to original source... Go to PubMed...
  3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121. Go to original source... Go to PubMed...
  4. Söderberg C, St?l P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602-608. Go to original source... Go to PubMed...
  5. Caldwell, SH, Oelsner, DH, Iezzoni, JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669. Go to original source... Go to PubMed...
  6. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1979. Go to original source... Go to PubMed...
  7. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Geneva: World Health Organization 1999.
  8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850. Go to original source... Go to PubMed...
  9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192. Go to original source... Go to PubMed...
  10. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol Hepatol; 2010; 25(4): 672-690. Go to original source... Go to PubMed...
  11. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105. Go to original source... Go to PubMed...
  12. Tajmer P. Fibróza jater. S. 35-46. In. Špičák J. Novinky v gastroenterologii a hepatologii. Grada 2008.
  13. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005; 59(Suppl 2): S359-S362. Go to original source... Go to PubMed...
  14. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078. Go to original source... Go to PubMed...
  15. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844. Go to original source... Go to PubMed...
  16. A Younossi ZM, Jarrar M, Nugent C, et al. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) Obesity Surgery 2008; 11(18): 1430-1437. Go to original source... Go to PubMed...
  17. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51(1): 121-129. Go to original source... Go to PubMed...
  18. Machytka E. Současné možnosti endoskopické terapie obezity. Int Med 2007; 9(5): 237-239.
  19. Goodman A. Orlistat provides no improvement over diet alone for steatohepatitis. Hepatology 2009; 49: 80-86. Go to original source... Go to PubMed...
  20. de Denus S, Spinler SA, Kristin Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004; 24(5): 584-591. Go to original source... Go to PubMed...
  21. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post hoc analysis. Lancet 2010; DOI: 10.1016/S0140-6736 (10)61272-X. http://www.thelancet.com. Go to original source... Go to PubMed...
  22. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Berni Canani R, Calignano A, Mattace Raso G, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009; 139(5): 905-911. Go to original source... Go to PubMed...
  23. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307. Go to original source... Go to PubMed...
  24. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115. Go to original source... Go to PubMed...
  25. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110. Go to original source... Go to PubMed...
  26. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003; 17(12): 713-718. Go to original source... Go to PubMed...
  27. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis Diabetes Care 2004; 27: 2057-2066. Go to original source... Go to PubMed...
  28. Ma X, Hua J, Li Z. Probiotics Improve High Fat Diet-induced Hepatic Steatosis and Insulin Resistance by Increasing Hepatic NKT cells. J Hepatol 2008; 49(5): 821-830. Go to original source... Go to PubMed...
  29. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49(3): 989-997. Go to original source... Go to PubMed...
  30. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005165. Go to original source...
  31. Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010; 45(7): 750-757. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.